Taysha Gene Therapies, Inc.

NASDAQ:TSHA

Biotechnology

Healthcare
$3.99 +1.53%

+$0.10 today

Market cap
$1.30B
Beta
1.18
P/E (TTM)
-17.7
EPS (TTM)
-$0.35
52W Low $2.25High $7.30

Volume 3.38M

Average 2.73M

TSHA Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Taysha Gene Therapies, Inc.NASDAQ: TSHA

Weighted Avg Shares (Diluted) · Q2 FY2026 · quarter ended Jun 2026

Weighted avg shares (diluted) grows, but more slowly than its trailing trend

Q2 FY2026 weighted avg shares (diluted) of 369.04M shares rose 23.8% year over year, behind the +35.4% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 0.7% from the prior quarter. Over 3 fiscal years it compounded at +93.8% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +23.8% toward the trailing-twelve-month pace of +35.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
369.04M+0.7% QoQ
Last fiscal yearDec 2025
319.71M+27.8% YoY
LTMJun 2026
352.17M+35.4% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+23.8%——
1 year+27.8%——
3-year CAGR+93.8%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
319.71M USD
Year-over-year change
+27.8%
4-year CAGR
+70.7%

Weighted Avg Shares (Diluted) vs competitors

How TSHA compares with its peers on the latest reported figures

  • TSHA's LTM Jun 2026 weighted avg shares (diluted) of 352.17M shares is the highest of the 9 companies compared; the peer median is 59.21M shares.
  • Its year-over-year change of +35.4% is the 2nd highest of 9, against a peer median of +10.3%.
  • Over three fiscal years its annual growth of +93.8% compares with a peer median of +17.9%.
TSHA Competitors Peer median
Weighted Avg Shares (Diluted) for TSHA and competitors
Company Period LTM YoY 3-year CAGR
TSHATaysha Gene Therapies, Inc.LTM Jun 2026352.17M +35.4%+93.8%
RCKTRocket Pharmaceuticals, Inc.LTM Mar 2026111.46M +12.7%+17.7%
SRPTSarepta Therapeutics, Inc.LTM Mar 2026108.39M +6.9%+6.2%
ABEOAbeona Therapeutics Inc.LTM Mar 202660.91M +28.1%+103.4%
FDMT4D Molecular Therapeutics, Inc.LTM Mar 202659.51M +7.9%+21.4%
VYGRVoyager Therapeutics, Inc.LTM Mar 202658.91M +1.6%+15.2%
RGNXREGENXBIO Inc.LTM Mar 202651.84M +1.8%+6.1%
BNTCBenitec Biopharma Inc.LTM Mar 202643.27M +112.6%+166.1%
NGNENeurogene Inc.LTM Mar 202620M +14.7%+18.2%
Peer median (excluding TSHA) 59.21M+10.3%+17.9%

Competitors are the stored peer set for TSHA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue02.5M15.45M8.33M9.77M
Cost of Revenue02.49M000
Gross Profit015K15.45M8.33M9.77M
Gross Margin—0.6%100.0%100.0%100.0%
Research & Development131.94M91.17M56.78M66M86.4M
Selling, General & Admin41.32M34.87M30.05M28.95M33.87M
Operating Expenses173.27M126.04M87.89M99.79M120.27M
Depreciation & Amortization492K2.49M1.37M1.25M1.15M
EBITDA(172.6M)(159.73M)(105.2M)(87.95M)(107.79M)
EBITDA Margin—-6384.1%-680.8%-1055.5%-1102.9%
Operating Income(173.27M)(126.03M)(72.44M)(91.46M)(110.5M)
Operating Margin—-5037.1%-468.8%-1097.6%-1130.6%
Interest Income172K249K3.57M6.94M9.22M
Interest Expense1.43M3.8M5M102K63K
Other Income / Expenses(1.26M)(39.99M)(39.13M)2.16M1.5M
Income Before Tax(174.52M)(166.01M)(111.57M)(89.3M)(109M)
Pre-Tax Margin—-6635.3%-722.1%-1071.6%-1115.3%
Income Tax Expense00000
Net Income(174.52M)(166.01M)(111.57M)(89.3M)(109M)
Net Margin—-6635.3%-722.1%-1071.6%-1115.3%
EPS (Basic)(4.64)(3.78)(0.96)(0.36)(0.34)
EPS (Diluted)(4.64)(3.78)(0.96)(0.36)(0.34)
Weighted Avg Shares37.65M43.95M116.12M250.13M319.71M
Weighted Avg Shares (Diluted)37.65M43.95M116.12M250.13M319.71M

Taysha Gene Therapies, Inc.

NASDAQ:TSHA

Intrinsic Alpha fair value

Locked

Current Price

$3.99

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.